FENC - Company ID 0001211583
The table below shows FENNEC PHARMACEUTICALS INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $15.11M | $12.46M | $9.65M | $8.75M | $6.97M | $7.26M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $49.00K | $29.00K | $107.00K | $94.00K | $97.00K | $157.00K |
FENNEC PHARMACEUTICALS INC. reported annual revenue of $44.64M for fiscal year 2025. That is down 6.1% from $47.54M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $3.19M |
| $6.75M |
| $6.96M |
| $5.87M |
| $6.12M |
| $6.86M |
| Operating income | -$119.00K | -$189.00K | -$2.73M | -$808.00K | -$5.20M | -$5.04M |
| Income tax | - | - | - | - | - | - |
| Net income | $201.00K | -$638.00K | -$3.15M | -$1.17M | -$5.74M | -$5.55M |
| EPS (diluted) | $0.01 | -$0.02 | -$0.11 | -$0.04 | -$0.21 | -$0.20 |